Exscientia Logo
Pipeline

Early Discovery

  • (WO)

    Oncology

  • (WO)

    Oncology

  • (WO)

    Oncology

  • (WO)

    Oncology

  • (CO)

    Oncology

    (Apeiron)
  • (CO)

    Oncology

    (EQRx)
  • (CO)

    Oncology

    (Huandong)
  • (PP)

    Oncology

    (BMS)
  • (PP)

    Oncology

    (BMS)
  • (PP)

    Oncology

    (BMS)
  • (PP)

    Oncology

    (Sanofi)
  • (PP)

    Oncology

    (Sanofi)
  • (CO)

    Inflammation & Immunity

    PARP1(EQRx)
  • (CO)

    Inflammation & Immunity

    (EQRx)
  • (PP)

    Inflammation & Immunity

    (BMS)
  • (PP)

    Inflammation & Immunity

    (BMS)
  • (PP)

    Inflammation & Immunity

    Bispecific Small Molecule(Sanofi)
  • (PP)

    Inflammation & Immunity

    (Sanofi)
  • (WO)

    Anti-infective

    (Gates)

Late Discovery

  • (CO)

    Oncology

    ENPP1(Rallybio)
  • (PP)

    Oncology

    (BMS)
  • (WO)

    Inflammation & Immunity

    NLRP3
  • (WO)

    Coronavirus

    M pro(Gates)
  • (CO)

    HPP

    ENPP1(Rallybio)
  • (CO)

    Psychiatry

    (Blue Oak)

Ind-Enabling

  • (CO)

    Transcriptionally Addicted Cancers

    CDK7(GTAEXS617) (Apeiron)
  • (PP)

    Oncology

    (BMS)
  • (PP)

    Inflammatory Diseases

    Kinase(BMS)

Phase 1 / 2

  • (Pilot)

    High Adenosine Signature Cancers

    A2A(EXS21546)

(WO) = Wholly Owned

(CO) = Co-owned

(PP) = Pharma Partnership

Does not include Exscientia-designed programmes that entered clinical trials through DSP collaboration